Concord is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022, supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Concord is amongst the few companies globally that have successfully and sustainably established and scaled up fermentation-based API manufacturing capabilities.
Read more about Concord Biotech Ltd. IPO
The below table has important dates with respect to the IPO allotment and listing.
| Finalization of Basis of Allotment | 11-Aug-23 |
| Initiation of Refunds | 14-Aug-23 |
| Credit of Shares to Demat Acct | 17-Aug-23 |
| IPO Shares Listing Date | 18-Aug-23 |
| UPI mandate expiry date | 21-Aug-23 |
In case you have not been allotted for any partial allotment of IPO shares, the blocked amount, if any, will be unblocked/released on or before UPI mandate expiry date as mentioned in the above table. Please reach out to your bank in case funds are not unblocked/released post the mandate expiry date.
